- AdventHealth Research Institute
Used after breast surgery, regional node irradiation (RNI) is generally a standard part of treatment for patients with pathologically positive axillary nodes and aims to reduce the risk of cancer recurrence by killing any remaining cancer cells in those nodes. However, with the increasing use and efficacy of neo-adjuvant chemotherapy, many patients who initially present with positive axillary lymph nodes become pathologically tumor free after neoadjuvant chemotherapy. The benefit of RNI in this population of patients was unclear.
The phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial explored that question. The results were recently published in the New England Journal of Medicine with Eleftherios “Terry” Mamounas, MD, medical director of the breast program and research activities at AdventHealth Cancer Institute, serving as lead author. The study found that patients with positive axillary lymph nodes who become pathologically tumor free after neoadjuvant chemotherapy have low rates of disease recurrence and do not receive a statistically significant or clinically meaningful benefit from RNI at 5 years, supporting a shift in treatment strategy.
Click below to read more.
Recent News
In our latest Clinician’s View, Dr. Seminerio shares her personal passion for improving care for patients with inflammatory bowel disease (IBD) and talks about how AdventHealth’s recently established...
Dr. Richard Pratley, Samuel E. Crockett Chair in Diabetes Research and Medical Director of AdventHealth Diabetes Institute, recently shared insights with Healio Endocrinology about the importance of...
Under the leadership of Principal Investigator Valeria Baldivieso, MD, and Sub-Investigator Chandan Reddy, MD, MS, FAANS, the AdventHealth Research Institute is recruiting patients for the Exablate...
For people with Type 1 diabetes (T1D), low blood sugar episodes—also known as hypoglycemia—can strike fast and hard. The body’s natural defense is to release hormones like glucagon to raise blood...
A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.
Dr. Richard Pratley, Samuel E. Crockett Chair in Diabetes Research and Medical Director of AdventHealth Diabetes Institute, recently shared insights with Healio Endocrinology about the importance of...
Under the leadership of principal investigator Michael Seidman, MD, AdventHealth Research Institute is participating in the multi-site Clinical Trial of Etanercept (TNF-alpha Blocker) for Treatment of...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
Dr. Kirk Erickson Joins the NavNeuro Podcast to Discuss the Connection Between Physical Activity and Brain Health
Results From IGNITE Research Study Published in the Medical Journal "Age and Ageing"
“We are at a pivotal point in our understanding of neuroscience and in particular, neuroplasticity – the ability of neural networks in the brain to change through growth and reorganization. This new...
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism, introduces a metagenomics-powered approach to accurately track dietary intake...